Sensei Biotherapeutics appoints two new directors, expanding board to five

Sensei Biotherapeutics, Inc.

Board increased from 3 to 5 members; Christopher W. Gerry (President & GC) and Phillip B. Donenberg appointed Feb 13, 2026.
Gerry already serves as President and General Counsel of the company.
Donenberg brings CFO and audit committee experience from Taysha, Tectonic, Jaguar Gene Therapy, and AveXis.
Donenberg will receive non-employee director compensation per 2025 proxy statement.
Each appointee entered standard indemnification agreement with the company.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.